Shopping Cart
Remove All
Your shopping cart is currently empty
Asenapine (Org 5222) is a 5-HT receptor, adrenergic receptor, dopamine receptor, and histamine receptor antagonist with antipsychotic effects that is used to treat schizophrenia and manic or mixed episodes associated with bipolar 1 disorder.721483-46-5

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $32 | In Stock | In Stock | |
| 5 mg | $72 | In Stock | In Stock | |
| 10 mg | $98 | In Stock | In Stock | |
| 25 mg | $168 | In Stock | In Stock | |
| 50 mg | $247 | In Stock | In Stock | |
| 100 mg | $365 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $80 | In Stock | In Stock |
| Description | Asenapine (Org 5222) is a 5-HT receptor, adrenergic receptor, dopamine receptor, and histamine receptor antagonist with antipsychotic effects that is used to treat schizophrenia and manic or mixed episodes associated with bipolar 1 disorder.721483-46-5 |
| Targets&IC50 | α2A-adrenoceptor:8.9 (pKi), α2C-adrenoceptor:8.9 (pKi), 5-HT2C receptor:10.5 (pKi), α1-adrenoceptor:8.9 (pKi), 5-HT6 receptor:9.6 (pKi), 5-HT2B receptor:9.8 (pKi), 5-HT7 receptor:9.9 (pKi), α2B-adrenoceptor:9.5 (pKi), D1 receptor:8.9 (pKi), 5-HT2A receptor:10.2 (pKi), 5-HT1A receptor:8.6 (pKi), 5-HT5 Receptor:8.8 (pKi), D3 receptor:9.4 (pKi), H1 Receptor:9.0 (pKi), D2 Receptor:8.9 (pKi), D4 Receptor:9.0 (pKi), H2 receptor:8.2 (pKi), 5-HT1B receptor:8.4 (pKi) |
| In vitro | In comparison with the antipsychotics, asenapine showed high affinity and a different rank order of binding affinities (pKi) for serotonin receptors (5-HT1A [8.6], 5-HT1B [8.4], 5-HT2A [10.2], 5-HT2B [9.8], 5-HT2C [10.5], 5-HT5 [8.8], 5-HT6 [9.6] and 5-HT7 [9.9]), adrenoceptors (alpha1 [8.9], alpha2A [8.9], alpha2B [9.5] and alpha2C [8.9]), dopamine receptors (D1 [8.9], D2 [8.9], D3 [9.4] and D4 [9.0]) and histamine receptors (H1 [9.0] and H2 [8.2])[2]. |
| In vivo | Asenapine (0.05-0.2 mg/kg, s.c.) induced a dose-dependent suppression of CAR (no escape failures recorded) and did not induce catalepsy. Additionally, it increased dopamine efflux in both the medial prefrontal cortex (mPFC) and the nucleus accumbens (NAc)[2]. |
| Synonyms | Org 5222, ME2136, HSDB 8061 |
| Molecular Weight | 285.77 |
| Formula | C17H16ClNO |
| Cas No. | 65576-45-6 |
| Smiles | [H][C@@]12CN(C)C[C@@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |
| Relative Density. | 1.231 |
| Color | Yellow |
| Appearance | Oil |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: Insoluble DMSO: 80 mg/mL (279.95 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (11.55 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.